Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › LA › New Orleans › NPI 1225450588
Hospital

Parish Hospital Service District for the Parish of Orleans - Dist a

Parish Hospital Service District for the Parish of Orleans - Dist a was paid $49.84M by Medicaid between Jan 2018 and Dec 2024, across 225 billing codes. Its largest line is 99284, emergency room visit (serious) — 26% of everything it billed.

33Billing provider infoPARISH HOSPITAL SERVICE DISTRICT FOR THE PARISH OF ORLEANS - DIST A
NEW ORLEANS, LA 70127
33aNPI1225450588assigned 01/06/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$49.84M
24GClaims688,730
24DCodes billed225
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Louisiana

Rank by total paid#8 of 96
Median peer was paid$5.17M
This provider vs. median9.6×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$500K$1.0M$1.5M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201862,650$4.45M
201976,035$5.27M
202063,766$3.72M
2021123,436$6.46M
2022123,129$7.98M
2023138,269$11.86M
2024incomplete101,445$10.10M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 26% 58,133 52,223 $12.90M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 18% 29,242 25,606 $8.95M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 11% 36,863 33,298 $5.45M
64635 4.0% 2,185 1,651 $2.01M
64493 3.6% 2,064 1,592 $1.77M
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 3.5% 21,258 17,130 $1.77M
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 2.6% 17,932 15,652 $1.31M
96361 Intravenous infusion, hydration; each additional hour 2.6% 12,606 8,825 $1.28M
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 2.5% 32,624 28,451 $1.24M
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 2.2% 21,434 18,845 $1.09M
64636 1.8% 2,243 1,595 $874K
64494 1.5% 2,277 1,494 $772K
213 more codes
70450 Computed tomography, head or brain; without contrast material 1.4% 2,512 $712K
62323 1.4% 2,461 $707K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 1.4% 17,711 $688K
96375 Therapeutic injection; each additional sequential IV push 1.2% 11,166 $617K
74177 Computed tomography, abdomen and pelvis; with contrast material 1.1% 602 $567K
71045 Radiologic examination, chest; single view <1% 10,180 $493K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 2,019 $458K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 11,334 $307K
80053 Comprehensive metabolic panel <1% 37,748 $282K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 10,477 $274K
71046 Radiologic examination, chest; 2 views <1% 3,585 $268K
81025 <1% 39,050 $244K
G0378 Hospital observation service, per hour <1% 1,629 $229K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 42,591 $228K
73721 Magnetic resonance imaging, any joint of lower extremity; without contrast material <1% 411 $218K
45385 Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) <1% 1,383 $216K
62321 <1% 682 $201K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 831 $146K
45380 Colonoscopy, flexible; with biopsy, single or multiple <1% 1,026 $143K
27096 <1% 89 $141K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,838 $132K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 4,553 $124K
G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk <1% 386 $121K
36415 Collection of venous blood by venipuncture <1% 55,103 $111K
73562 <1% 1,040 $108K
73560 <1% 1,039 $93K
99213 Doctor's office visit, returning patient (routine) <1% 2,748 $90K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 909 $88K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 4,173 $88K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 868 $77K
C1776 Joint device (implantable) <1% 33 $75K
99214 Doctor's office visit, returning patient (more involved) <1% 1,499 $74K
84484 <1% 8,281 $71K
64490 <1% 70 $70K
64483 <1% 44 $68K
73564 <1% 389 $64K
C1713 Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) <1% 756 $60K
76816 Ultrasound, pregnant uterus, real time with image documentation, follow-up <1% 568 $57K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 2,043 $56K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 2,042 $56K
0001A <1% 1,542 $52K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 2,377 $49K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 94 $46K
0002A <1% 1,332 $45K
C9290 Injection, bupivacaine liposome, 1 mg <1% 495 $43K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 1,436 $42K
80305 <1% 4,695 $41K
J7030 Infusion, normal saline solution , 1000 cc <1% 4,028 $40K
20610 <1% 30 $40K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 362 $39K
64491 <1% 82 $38K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 6,519 $37K
87634 <1% 597 $37K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) <1% 4,205 $37K
81001 <1% 15,803 $37K
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 4,841 $37K
45378 Colonoscopy, flexible; diagnostic, including collection of specimen(s) <1% 94 $35K
83880 <1% 1,559 $35K
83690 <1% 6,886 $35K
97161 <1% 658 $33K
0012A <1% 1,060 $32K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 1,393 $31K
76811 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed <1% 152 $29K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 297 $28K
94664 <1% 282 $28K
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 3,387 $27K
0011A <1% 999 $27K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,689 $24K
73130 <1% 263 $23K
81003 <1% 14,047 $22K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 44 $21K
J0780 Injection, prochlorperazine, up to 10 mg <1% 1,394 $21K
87086 Culture, bacterial; quantitative colony count, urine <1% 3,140 $21K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 455 $20K
94644 <1% 366 $20K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 805 $18K
80061 Lipid panel <1% 1,652 $17K
J2704 Injection, propofol, 10 mg <1% 6,640 $17K
0004A <1% 486 $17K
73030 <1% 174 $17K
64633 <1% 15 $16K
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 457 $15K
J0558 Injection, penicillin g benzathine and penicillin g procaine, 100,000 units <1% 52 $15K
73221 <1% 13 $15K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 283 $14K
0071A <1% 320 $13K
83036 Hemoglobin; glycosylated (A1C) <1% 1,827 $13K
0013A <1% 317 $12K
82550 <1% 2,774 $12K
80048 Basic metabolic panel (calcium, ionized) <1% 2,109 $12K
87081 <1% 1,500 $10K
80047 <1% 1,140 $9K
73630 <1% 96 $9K
71275 Computed tomographic angiography, chest, with contrast material <1% 12 $8K
73610 <1% 89 $7K
72170 <1% 67 $7K
64634 <1% 15 $7K
29827 <1% 18 $7K
84443 Thyroid stimulating hormone (TSH) <1% 499 $6K
0031A <1% 201 $6K
83735 <1% 1,416 $6K
J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg <1% 227 $6K
G0105 Colorectal cancer screening; colonoscopy on individual at high risk <1% 19 $5K
80050 General health panel <1% 155 $5K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 195 $5K
82150 <1% 903 $5K
0072A <1% 118 $5K
J0690 Injection, cefazolin sodium, 500 mg <1% 1,870 $5K
73502 <1% 42 $4K
72100 <1% 39 $4K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 2,410 $4K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 197 $4K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 2,817 $3K
85027 <1% 695 $3K
76819 Fetal biophysical profile; without non-stress testing <1% 38 $3K
87430 <1% 262 $3K
82962 <1% 1,321 $3K
93350 <1% 12 $3K
82947 <1% 1,655 $3K
90674 <1% 182 $3K
93017 <1% 13 $2K
J2360 Injection, orphenadrine citrate, up to 60 mg <1% 125 $2K
80076 <1% 270 $2K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 3,000 $2K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 32 $2K
85610 <1% 566 $2K
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 279 $2K
G0433 Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening <1% 215 $2K
J2270 Injection, morphine sulfate, up to 10 mg <1% 262 $2K
84100 <1% 493 $2K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 262 $2K
J8540 Dexamethasone, oral, 0.25 mg <1% 705 $2K
74022 <1% 12 $1K
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 369 $1K
74019 <1% 14 $1K
73110 <1% 14 $1K
83605 <1% 158 $1K
86706 <1% 117 $1K
80074 <1% 39 $1K
90715 <1% 25 $933.50
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 4,700 $930.69
87210 <1% 258 $915.84
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 46 $884.19
C1751 Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) <1% 714 $865.49
86803 <1% 70 $826.31
87070 <1% 96 $818.95
86756 <1% 53 $808.16
87088 <1% 114 $776.64
77067 Screening mammography, bilateral, including computer-aided detection <1% 12 $748.70
85379 <1% 110 $741.65
86408 <1% 23 $716.21
J0500 Injection, dicyclomine hcl, up to 20 mg <1% 23 $647.91
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 1,307 $601.26
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 553 $575.84
0064A <1% 13 $553.14
J3370 Injection, vancomycin hcl, 500 mg <1% 21 $549.31
86708 <1% 42 $475.24
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 30 $462.57
J3490 Unclassified drugs <1% 170 $455.00
0054A <1% 12 $454.58
83090 <1% 40 $430.08
86140 <1% 97 $414.40
96376 <1% 12 $394.47
84481 <1% 36 $384.64
85730 <1% 85 $381.05
86704 <1% 27 $334.07
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 12,871 $330.36
85651 <1% 85 $328.37
J2919 Injection, methylprednisolone sodium succinate, 5 mg <1% 38 $325.77
86592 <1% 100 $324.54
J3010 Injection, fentanyl citrate, 0.1 mg <1% 911 $310.28
85014 <1% 241 $308.53
87340 <1% 27 $298.65
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 208 $248.11
G0475 Hiv antigen/antibody, combination assay, screening <1% 29 $228.85
80320 <1% 32 $189.40
87077 <1% 26 $185.84
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 27 $167.53
J7644 Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram <1% 78 $129.23
84439 <1% 15 $126.28
84702 <1% 12 $90.30
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 35 $84.23
J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme <1% 14 $75.00
91300 <1% 3,447 $62.08
J0171 Injection, adrenalin, epinephrine, 0.1 mg <1% 263 $59.06
J7611 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg <1% 48 $51.14
A6258 Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing <1% 113 $45.94
85018 <1% 19 $37.92
A6223 Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing <1% 362 $34.93
91301 <1% 2,601 $31.60
J1170 Injection, hydromorphone, up to 4 mg <1% 104 $30.27
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 49 $29.29
85652 <1% 12 $27.00
Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml <1% 15 $23.67
J2550 Injection, promethazine hcl, up to 50 mg <1% 23 $19.45
J0688 Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg <1% 14 $16.04
J2371 Injection, phenylephrine hydrochloride, 20 micrograms <1% 49 $14.68
88342 <1% 294 $9.73
A6222 Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing <1% 305 $1.66
91305 <1% 41 $0.02
88304 0% 14 $0.00
91307 0% 445 $0.00
91303 0% 234 $0.00
64450 0% 55 $0.00
91306 0% 13 $0.00
J0330 Injection, succinylcholine chloride, up to 20 mg 0% 12 $0.00
J2370 Injection, phenylephrine hcl, up to 1 ml 0% 22 $0.00
99001 0% 2,071 $0.00
G1004 Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program 0% 116 $0.00
88312 0% 88 $0.00
J7120 Ringers lactate infusion, up to 1000 cc 0% 26 $0.00
Q0163 Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen 0% 12 $0.00
J2710 Injection, neostigmine methylsulfate, up to 0.5 mg 0% 13 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGARNER, MARIO (CHIEF EXECUTIVE OFFICER)